Vor Biopharma Inc. (VOR)

NMS – Real Time Price. Currency in USD

16.55

+0.08 (0.49%)

Market open: May 13, 2026, 9:44 AM EDT

07.05.2026

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

04.05.2026

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on May 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 53,400 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 11,350 shares of Vor Bio's common stock to 6 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

20.04.2026

Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

08.04.2026

Vor Biopharma: It's A Game Of Wait And See

Vor Biopharma Inc. has pivoted to immunology, raising over $500m in 2025 to advance telitacicept for U.S. approval. VOR holds $530m cash, extending its runway into 2029, but faces significant dilution risk from outstanding warrants and equity plans. Telitacicept, already approved in China for multiple indications, must now clear pivotal Phase 3 US trials, with data not expected until 2027.

02.04.2026

Vor Biopharma (VOR) Upgraded to Buy: Here's Why

Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

02.04.2026

Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 107.8% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

01.04.2026

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 42,650 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 9,050 shares of Vor Bio's common stock to 9 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

Videos

No Data

There is no data to display

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease

30.03.2026

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease

First and only dual BAFF/APRIL inhibitor in primary Sjögren's disease, one of the largest autoimmune diseases without an approved therapy First and only dual BAFF/APRIL inhibitor in primary Sjögren's disease, one of the largest autoimmune diseases without an approved therapy

Vor Biopharma Inc. (VOR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Vor Biopharma Inc. (VOR)

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?

Vor Biopharma: It's A Game Of Wait And See

Vor Biopharma (VOR) Upgraded to Buy: Here's Why

Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?

Vor Biopharma: It's A Game Of Wait And See

Vor Biopharma (VOR) Upgraded to Buy: Here's Why

Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease

Search stocks

Vor Biopharma Inc. (VOR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Vor Biopharma Inc. (VOR)

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?

Vor Biopharma: It's A Game Of Wait And See

Vor Biopharma (VOR) Upgraded to Buy: Here's Why

Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?

Vor Biopharma: It's A Game Of Wait And See

Vor Biopharma (VOR) Upgraded to Buy: Here's Why

Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease